Organon

Daré Bioscience Reports Full Year 2022 Financial Results and Provides a Company Update

Retrieved on: 
Thursday, March 30, 2023
Cream, Organon, U.S.–Canada Team Tournament (Go), IVR, Hot, Vaginitis, Bacterial vaginosis, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Human services, Vaginal discharge, Office of Inspector General, U.S. Department of Health and Human Services, Woman, Vulvar vestibulitis, NICHD, ID, Bangladesh Technical Education Board, Trial of the century, Hormone, Tamoxifen, Development, Bayer, Patient, Place of birth, Webcast, Human development, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bacteria, Progesterone, IDE, Research, FDA, NIH, Female, Birth control, Pharmaceutical industry, Cryptocurrency

SAN DIEGO, March 30, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2022 and provided a company update.

Key Points: 
  • A proprietary, investigational cream formulation of sildenafil, the active ingredient in Viagra®, for topical administration to treat female sexual arousal disorder.
  • Financial Highlights for the Year ended December 31, 2022
    Cash and cash equivalents: $34.7 million at December 31, 2022, compared to $51.7 million at December 31, 2021.
  • Research and development expenses: $30.0 million in fiscal 2022 as compared to $30.6 in the prior year.
  • Daré will host a conference call and live webcast today at 4:30 p.m. Eastern Time to review financial results for the year ended December 31, 2022 and to provide a company update.

Fosun Pharma Announces its 15th Corporate Social Responsibility Report: Continuous Innovation for the Benefit of the Public

Retrieved on: 
Wednesday, March 29, 2023
Online, Social responsibility, Artesunate, Idiopathic pulmonary fibrosis, Rituximab, Fosun Pharma, MPP, COVID-19, Family, Spasm, Multimedia, Corporate social responsibility, Axicabtagene ciloleucel, CSR, Medicines Patent Pool, Psoriasis, The Bund Finance Center, Occupational Safety and Health Act 1994, MSCI, Health Level Seven International, Patient, Annual report, Adalimumab, Developed country, EHS, Trastuzumab, Diagnosis, ESG, R, Rare, Immunodeficiency, Health, Pulmonary hypertension, Environment, Air pollution, RMB, Safety, Malaria, Pharmaceutical industry, Azvudine, Eurofarma, Organon

As before, Fosun Pharma achieved a five-star rating, as evaluated by the China CSR Report Rating Expert Committee, for the outstanding performance reported.

Key Points: 
  • As before, Fosun Pharma achieved a five-star rating, as evaluated by the China CSR Report Rating Expert Committee, for the outstanding performance reported.
  • Through its strengths, Fosun Pharma is also helping to solve drug accessibility problems in developing countries and underdeveloped areas.
  • Moreover, Fosun Pharma owns industry-leading capability in in&out licensing and internationalization, maximizing the value of each innovative product.
  • Furthermore, Fosun Pharma is continually striving for excellence, improving its product quality and medical services, and launched Fosun Pharma Operation Excellence (FOPEX) in 2016.

NewHydrogen Names Steven Hill as Vice President

Retrieved on: 
Monday, March 20, 2023
University, Solid oxide electrolyzer cell, Engineering, Marketing, Schering-Plough, IE Business School, Platinum, Research, AstraZeneca, Technology management, Associate, Business administration, Investment, Daiichi Sankyo, OTC, Iridium, Master of Business Administration, UCLA, Hill, Utah Valley University, Fine chemical, Management, Science, Aviation, Organon

SANTA CLARITA, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- NewHydrogen, Inc. (OTC:NEWH), the developer of a breakthrough technology to produce low-cost green hydrogen, today announced that Steven Hill will serve as Vice President and member of the company’s board of directors, effective immediately. Hill is an accomplished sales executive with over 20 years of experience in the biopharmaceutical industry.

Key Points: 
  • SANTA CLARITA, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- NewHydrogen, Inc. (OTC:NEWH), the developer of a breakthrough technology to produce low-cost green hydrogen, today announced that Steven Hill will serve as Vice President and member of the company’s board of directors, effective immediately.
  • Hill brings to NewHydrogen extensive experience and business knowledge gained from working in the pharmaceutical industry.
  • Hill also served as a Managing Member of Hill Investments, LLC, a real estate investment and design group during which time Mr. Hill consulted on property development and managed real estate investments.
  • “We are excited to welcome Steve to NewHydrogen, and expect that he will immediately strengthen our management team,” said Dr. David Lee, CEO of NewHydrogen.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organon & Co. - OGN

Retrieved on: 
Friday, March 10, 2023
OGN, News, Organon & Co., NYSE, Organon, Cryptocurrency, Private investigator

NEW YORK, March 10, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Organon & Co. (“Organon” or the “Company”) (NYSE: OGN).

Key Points: 
  • NEW YORK, March 10, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Organon & Co. (“Organon” or the “Company”) (NYSE: OGN).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Organon and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

XOMA Reports Full-Year 2022 Financial Results and Provides Update to the Acceleration of its Differentiated Royalty Monetization Strategy

Retrieved on: 
Thursday, March 9, 2023
Burns, Acquisition, Sonnet, Employment, R, Research, G&A, Eye, Compugen, Continuity, Retirement, Organon, Music, Bank, Cryptocurrency, Novartis, Rezolution Pictures, Janssen, Takeda

EMERYVILLE, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, reported its full year 2022 financial results and provided an operational update on the Company’s actions to accelerate XOMA’s differentiated biotech royalty and milestone acquisition strategy.

Key Points: 
  • “Since joining the Company in January, Brad Sitko and I have continually been impressed by the opportunities in front of XOMA.
  • We are assessing each potential opportunity with an eye to maximizing shareholder returns,” stated Owen Hughes, Executive Chairman of XOMA.
  • Revenues for the fourth quarter and year ended December 31, 2022, were $1.5 million and $6.0 million, respectively.
  • On December 31, 2022, XOMA had cash and cash equivalents of $57.8 million and no debt on its balance sheet.

Organon Launches “Her Plan is Her Power,” a New Global Initiative to Reduce Unplanned Pregnancies Where Need is Great and Disparities Exist

Retrieved on: 
Tuesday, March 7, 2023
Other Philanthropy, Women, Medical Supplies, Managed Care, General Health, DEI (Diversity, Equity and Inclusion), Family, Socially Responsible Investing, Social Services, Other Health, Consumer, Environmental, Social and Governance (ESG), Pharmaceutical, Teens, Baby, Maternity, Professional Services, Philanthropy, Other Education, Health, Education, Child, Science, NYSE, Pregnancy, Equity, UNFPA, United Nations Commission on the Status of Women, Equalizer, Inauguration, Environment, International, Division, Communication, SRH, Multimedia, NGO, Investment, OGN, United Nations, Organization, Birth control, Woman, Organon

View the full release here: https://www.businesswire.com/news/home/20230307005176/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230307005176/en/
    Unplanned pregnancies are in part caused by a lack of access to contraceptive information and services.
  • Globally, of the 257 million women who want to avoid pregnancy, almost 67% are not using any contraceptive method.
  • “The staggering number of unintended pregnancies that occur globally each year – nearly half of all pregnancies – require the power of public-private collaboration.
  • In 2022, Organon made a commitment to help prevent 120 million unplanned pregnancies in the world’s least-developed countries by 2030 as part of FP2030 .

Inception Fertility's 2023 Annual Summit Celebrates the Patient Experience and Honors Team Members and Clinics for their Dedication to Aspiring Parents

Retrieved on: 
Thursday, March 9, 2023
Physician, Digital, Science, Health, Ferring Pharmaceuticals, Research, Embryology, Fertility, Aspire, AON, The Cooper Companies, Medicine, Labcorp, HUB, Patient experience, Patient, Mental health, Cigna, RMG, Work, Safety, Parent, Nursing, Organon, Inception

HOUSTON, March 9, 2023 /PRNewswire/ -- Inception Fertility™ (Inception), the largest provider of comprehensive fertility services in North America, announces today the winners of its 2023 Patient Experience Awards, presented at the 2023 Annual Inception Physician Summit, a gathering of Inception physicians and team members across its expansive family of brands, that celebrates their contributions to providing aspiring parents with the highest level of professional, individualized care. The 2023 Patient Experience Awards winners were part of Inception's family of brands, which includes the clinical network, The Prelude Network®.

Key Points: 
  • The 2023 Patient Experience Awards gala recognizes the contributions and commitments of Inception family members; the annual summit brings together fertility leaders to discuss advances and research in fertility care.
  • The 2023 Patient Experience Awards winners were part of Inception's family of brands, which includes the clinical network, The Prelude Network ®.
  • The annual summit also serves as an opportunity for Inception members to collaborate on best practices for patient care, define the future of Inception, and to continue moving the industry forward through advancements in science, medicine, and individualized patient experience.
  • This year's awards include the Patient Experience Leader Award, CEO's Patient Experience Emerging Leader Award, Patient Experience Tenet Leaders Awards, Patient Experience Outstanding Practice Award, and the Patient Experience Legacy Award.

Organon Canada receives the Women in Governance (WiG) Parity Certification SME, further demonstrating its commitment to gender parity in the workplace

Retrieved on: 
Friday, March 3, 2023
Parity, Woman, Gender, National Employees' Trade Union, Heart, Certification, Sustainable Development Goals, NYSE, Human, Human resources, St. John's International Women's Film Festival, Health, UN, OGN, Environment, Organization, Policy, International Women's Day, Culture, Wig, Sustainable development, Workplace, Nursing, Organon, QC

The WiG Parity Certification SME is a national benchmark recognizing notable organizations for their ongoing efforts and commitments to gender parity in the workplace.

Key Points: 
  • The WiG Parity Certification SME is a national benchmark recognizing notable organizations for their ongoing efforts and commitments to gender parity in the workplace.
  • "This recognition is a strong testament to our ongoing commitment to gender equity in the workplace and beyond," says Michael Casia, President and Managing Director at Organon Canada.
  • "At Organon Canada, our mission is to deliver impactful solutions which help to envision a better and healthier every day for everyone, with a focus on women.
  • To learn more about Organon Canada's vision and values as it relates to diversity, equity, inclusion and belonging, visit organon.com/Canada-en/mission-vision-values/ .

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organon & Co. - OGN

Retrieved on: 
Wednesday, March 1, 2023
NYSE, OGN, Organon & Co., Organon, News, Cryptocurrency, Private investigator

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Organon & Co. (“Organon” or the “Company”) (NYSE: OGN).

Key Points: 
  • NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Organon & Co. (“Organon” or the “Company”) (NYSE: OGN).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Organon and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

Ahead of International Women's Day, Organon Canada Spotlights the Importance of Supporting Women's Equity While Highlighting the Cost of Not Investing in Their Health

Retrieved on: 
Monday, February 27, 2023
International Women's Day, Diagnosis, Menopause, NYSE, Organization, Woman, Partnership, Research, OGN, Culture, Government, Gender, Human resources, AWHF, Medicine, International Women's Health Coalition, Friends, Endometriosis, Taboo, Health, Women's health, Light, Pharmaceutical industry, Nursing, Birth control, Organon, QC

KIRKLAND, QC, Feb. 27, 2023 /CNW/ - For far too long, women's health issues have been underfunded, under researched and underserved.

Key Points: 
  • KIRKLAND, QC, Feb. 27, 2023 /CNW/ - For far too long, women's health issues have been underfunded, under researched and underserved.
  • In fact, only 24% of women felt their physician is very knowledgeable about gynecological and reproductive health.
  • With Organon Canada's support and leadership, we can truly make a meaningful difference in the name of women's health.
  • For further insights and to view additional data from the Alberta Women's Health Foundation survey, visit albertawomenshealthfoundation.org/our-impact .